Does Moonlighting protein GAPDH hold the key to develop a radical new therapy against HIV/AIDS?
| Project/Area Number |
25670062
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Environmental and hygienic pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
SHOGO Misumi 熊本大学, 生命科学研究部, 教授 (40264311)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | HIV-1 / GAPDH / 宿主因子 / ウイルス複製 / 根治療法 / HIV / 逆転写過程 |
|---|
| Outline of Final Research Achievements |
Human immunodeficiency virus type 1 (HIV-1) replication is positivity or negatively regulated by host proteins. Some of the host proteins are incorporated inside the virions during assembly and play essential roles. Here, we revealed that glycersldehyde 3-phosohate dehydrogenase (GAPDH), known as “moonlighting” protein, is incorporated into HIV-1 virion and decreases the packaging efficiency of lysyl-tRNAsynthetase (LysRS) and tRNALys3 into particles. The GAPDH-packaging-defective virus showed an increased infectivity, whereas the enhanced-GAPDH-packaging virus showed a decreased infectivity. Elucidating the inhibitory mechanism of GAPDH in HIV replication may help us to develop an novel HIV therapeutic strategy.
|
Report
(3 results)
Research Products
(8 results)
